Capparelli C - Search Results

1

ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.

Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. Capparelli C, et al. Cancer Res. 2015 Sep 1;75(17):3554-67. doi: 10.1158/0008-5472.CAN-14-2959. Epub 2015 Jul 23. Cancer Res. 2015. PMID: 26206558 Free PMC article.

2

Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.

Capparelli C, Rosenbaum S, Berger AC, Aplin AE. Capparelli C, et al. J Biol Chem. 2015 Oct 2;290(40):24267-77. doi: 10.1074/jbc.M115.657270. Epub 2015 Aug 12. J Biol Chem. 2015. PMID: 26269601 Free PMC article.

3

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE. Vu HL, et al. Among authors: capparelli c. J Invest Dermatol. 2016 Feb;136(2):453-463. doi: 10.1016/j.jid.2015.11.012. Epub 2015 Nov 20. J Invest Dermatol. 2016. PMID: 26967478 Free PMC article.

4

ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.

Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, Berger AC, Davies MA, Gershenwald JE, Krepler C, Aplin AE. Capparelli C, et al. Cancer Res. 2018 Oct 1;78(19):5680-5693. doi: 10.1158/0008-5472.CAN-18-1001. Epub 2018 Aug 16. Cancer Res. 2018. PMID: 30115691 Free PMC article.

5

The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.

Erkes DA, Field CO, Capparelli C, Tiago M, Purwin TJ, Chervoneva I, Berger AC, Hartsough EJ, Villanueva J, Aplin AE. Erkes DA, et al. Among authors: capparelli c. Pigment Cell Melanoma Res. 2019 Sep;32(5):687-696. doi: 10.1111/pcmr.12788. Epub 2019 May 20. Pigment Cell Melanoma Res. 2019. PMID: 31063649 Free PMC article.

6

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.

Tiago M, Capparelli C, Erkes DA, Purwin TJ, Heilman SA, Berger AC, Davies MA, Aplin AE. Tiago M, et al. Among authors: capparelli c. Br J Cancer. 2020 Mar;122(6):789-800. doi: 10.1038/s41416-019-0724-y. Epub 2020 Jan 14. Br J Cancer. 2020. PMID: 31932756 Free PMC article.

7

Combined SHPments: An Effective Therapeutic Strategy for MPNST.

Aplin AE, Capparelli C. Aplin AE, et al. Among authors: capparelli c. Cancer Res. 2021 Jan 15;81(2):266-267. doi: 10.1158/0008-5472.CAN-20-3834. Cancer Res. 2021. PMID: 33452215 Free PMC article.

8

SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.

Rosenbaum SR, Tiago M, Caksa S, Capparelli C, Purwin TJ, Kumar G, Glasheen M, Pomante D, Kotas D, Chervoneva I, Aplin AE. Rosenbaum SR, et al. Among authors: capparelli c. Cell Rep. 2021 Dec 7;37(10):110085. doi: 10.1016/j.celrep.2021.110085. Cell Rep. 2021. PMID: 34879275 Free PMC article.

9

Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.

Capparelli C, Purwin TJ, Glasheen M, Caksa S, Tiago M, Wilski N, Pomante D, Rosenbaum S, Nguyen MQ, Cai W, Franco-Barraza J, Zheng R, Kumar G, Chervoneva I, Shimada A, Rebecca VW, Snook AE, Hookim K, Xu X, Cukierman E, Herlyn M, Aplin AE. Capparelli C, et al. Nat Commun. 2022 Mar 16;13(1):1381. doi: 10.1038/s41467-022-28801-y. Nat Commun. 2022. PMID: 35296667 Free PMC article.

10

Packing a Punch against PD-L1.

Capparelli C, Aplin AE. Capparelli C, et al. Cancer Discov. 2022 Jun 2;12(6):1413-1415. doi: 10.1158/2159-8290.CD-22-0301. Cancer Discov. 2022. PMID: 35652219

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters